

Bibliography

- Alves VA, Wakamatsu A, Kanamura CT, et al. The importance of fixation in immunohistochemistry: distribution of vimentin and cytokeratins in samples fixed in alcohol and formol. *Rev Hosp Clin Fac Med Sao Paulo*. 1992; **47**:19-24.
- Alves VAF, Bacchi CE, Vassallo J. Manual de Imuno-histoquímica. São Paulo: Sociedade Brasileira de Patologia. 1999; **23**:17-20.
- Ambrosone C, Freudenheim J, Graham S, Marshall J, Vena J, Brasure J, et al. Cytochrome P450IA1 and glutathione S-transferase (M1) genetic polymorphisms and postmenopausal breast cancer risk. *Cancer Res*. 1995; **55**:3483-3485.
- Anderson SF, Schlegel BP, Nakajima T, Wolpin ES, Parvin JD. BRCA1 protein is linked to the RNA polymerase II holoenzyme complex via RNA helicase A. *Nat Genet*. 1998; **19**:254-6.
- Antoniou AC, Pharoah PD, Narod S, et al. Breast and ovarian cancer risks to carriers of the BRCA1 5382insC and 185delAG and BRCA2 6174delT mutations: a combined analysis of 22 population based studies. *J Med Genet*. 2005; **42**:602-603.
- Aprelikova O, Pace AJ, Fang B, Koller BH, Liu ET. BRCA1 is a selective co-activator of 14-3-3 sigma gene transcription in mouse embryonic stem cells. *J Biol Chem*. 2001; **276**:25647-50.
- Ausubel F, et al. Current Protocols in Molecular Biology. Part 1: E. coli, plasmids, and bacteriophages. *Current Protocols*. 1993.
- Avrameas S, Uriel J. Method of antigen and antibody labelling with enzymes and its immunodiffusion application. *C R Acad Sci Hebd Seances Acad Sci D*. 1966; **262**:2543-5.

- Awioro OG. Histochemistry and tissue pathology, principles and techniques. *Claverianum press*, Nigeria. 2010
- Balaton AL, Coindre JM, Collin F, et al. Recommendations for the immunohistochemical evaluation of hormone receptors on paraffin sections of breast cancer. *Ann Pathol*. 1996; **16**:144-8.
- Bartel TB, Haessler J, Brown TL, et al. F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma. *Blood*. 2009; **114**(10):2068-2076.
- Baumann P, Benson FE, West SC. Human Rad51 protein promotes ATP-dependent homologous pairing and strand transfer reactions *in vitro*. *Cell*. 1996; **87**:757-66.
- Bar-Sade RB, Kruglikova A, Modan B, Gak E, Hirsh-Yechezkel G, et al. The 185DelAG BRCA1 mutation originated before the dispersion of Jews in the diaspora and is not limited to Ashkenazim. *Human Molecular Genetics*. 1998; **7**:801-805.
- Bell DW, Varley JM, Szydlo TE, Kang DH, Wahrer DC, Shannon KE, Lubratovich M, Verselis SJ, Isselbacher KJ, Fraumeni JF, Birch JM, Li FP, Garber JE, Haber DA. Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. *Science* 1999; **286**:2528-31.
- Bin Q, Luo J. Role of Polymorphisms of *GSTM1*, *GSTT1* and *GSTP1* Ile105val in Hodgkin and Non-Hodgkin Lymphoma Risk: A Human Genome Epidemiology (Huge) Review. *Leuk Lymphoma*. 2013; **54**(1):14-20.
- Blay P, Santamaria I, Pitipt AS, Luque M, Alvarado MG, Lastra A, Fernandez Y, Paredes A, Freije JMP, Balbin M. Mutational analysis of BRCA1 and

- BRCA2 in hereditary breast and ovarian cancer families from Asturias (Northern Spain). *BMC Cancer*. 2013; **13**:243.
- Robrow MN, Harris TD, Shaughnessy KJ, et al. Catalyzed reporter deposition, a novel method of signal amplification. Application to immunoassays. *J Immunol Methods*. 1989; **125**:279-85.
- Robrow MN, Litt GJ, Shaughnessy KJ, et al. The use of catalyzed reporter deposition as a means of signal amplification in a variety of formats. *J Immunol Methods*. 1992; **150**:145-9.
- Bodey B. The significance of immunohistochemistry in the diagnosis and therapy of neoplasms. *Expert Opin Biol Ther*. 2002; **2**:371-93.
- Brandtzaeg P. The increasing power of immunohistochemistry and immunocytochemistry. *J Immunol Methods*. 1998; **216**:49-67.
- Bulmer D. Observations on histological methods involving the use of phosphotungstic and phosphomolybdic acids, with particular reference to staining with phosphotungstic acid /haematoxylin. *Q. J. Microsc. Sci*. 1962; **103**: 311-323.
- Burke W, Daly M, Garber J, et al; Cancer Genetics Studies Consortium. Recommendations for follow-up care of individuals with an inherited predisposition to cancer, II: BRCA1 and BRCA2. *JAMA*. 1997; **277**:997-1003.
- Cattoretti G, Becker MH, Key G, et al. Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detects proliferating cells in microwave-processed formalin-fixed paraffin sections. *J Pathol*. 1992; **168**:357-63.

- Celeste A, Petersen S, Romanienko PJ, Fernandez-Capetillo O, Chen HT, Sedelnikova OA, et al. Genomic instability in mice lacking histone H2AX. *Science*. 2002; **296**:922-7.
- Chapman MS, Verma IM. Transcriptional activation by BRCA1. *Nature*. 1996; **382**:678-9.
- Charrier J, Maugard C, LeMevel B, Bignon Y. Allelotype influence at glutathione S-transferase M1 locus on breast cancer susceptibility. *Br. J. Cancer*. 1999; **79**:346-353.
- Chaturvedi P, Eng WK, Zhu Y, Mattern MR, Mishra R, Hurle MR, Zhang X, Annan RS, Lu Q, Faucette LF, Scott GF, Li X, Carr SA, Johnson RK, Winkler JD, Zhou BB. Mammalian Chk2 is a downstream effector of the ATM-dependent DNA damage checkpoint pathway. *Oncogene*. 1999; **18**:4047-54.
- Chen J, Silver DP, Walpita D, Cantor SB, Gazdar AF, Tomlinson G, Couch FJ, Weber BL, Ashley T, Livingston DM, Scully R. Stable interaction between the products of the BRCA1 and BRCA2 tumor suppressor genes in mitotic and meiotic cells. *Mol Cell*. 1998; **2**:317-28.
- Chen JJ, Shen HC, Rivera RLA, Zhang Y, Di X, Zhang B. Mislocalization of death receptors correlates with cellular resistance to their cognate ligands in human breast cancer cells. *Oncotarget*. 2012; **3(8)**:833-42.
- Chen S, Iversen ES, Friebel T, Finkelstein D, Weber BL, Eisen A, et al. Characterization of BRCA1 and BRCA2 mutations in a large United States sample. *J Clin Oncol*. 2006; **24**:863–871.
- Chiba N, Parvin JD. The BRCA1 and BARD1 association with the RNA polymerase II holoenzyme. *Cancer Res*. 2002; **62**:4222-8.

- Clark G. Comparison of various oxidants for alum hematoxylin. *Stain Technol.* 1974; **49**:225-227.
- Clark SI, Rodriguez Am, Snyder RR, Hankins GD, Boehning D. Structure-Function of the tumor suppressor BRCA1. *Comput Struct Biotechnol J.* 2012; **1(1)**. Pii: e201204005.
- Coons AH, Creech HJ, Jones RN. Immunological properties of an antibody containing a fluorescence group. *Proc Soc Exp Biol Med.* 1941; **47**:200-2
- Cordell JL, Falini B, Erber WN, et al. Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes). *J Histochem Cytochem.* 1984; **32**:219-29.
- Cortez D, Wang Y, Qin J, Elledge SJ. Requirement of ATM-dependent phosphorylation of brca1 in the DNA damage response to double-strand breaks. *Science.* 1999; **286**:1162-6.
- Culling CFA. Handbook of histopathological and histochemical techniques. *3rd ed. London: Butterworth, 1974.*
- Dancey JE, Bedard PL, Onetto N, Hudson J. The genetic basis for cancer treatment decisions. *Cell.* 2012;**148**: 409-20.
- Davies AA, Masson JY, McIlwraith MJ, Stasiak AZ, Stasiak A, Venkitaraman AR, West SC. Role of BRCA2 in control of the RAD51 recombination and DNA repair protein. *Mol Cell.* 2001; **7**: 273-82.
- Deng CX. *BRCA1*: cell cycle checkpoint, genetic instability, DNA damage response and cancer evolution. *Nucleic Acids Research.* 2006; **34(5)**:1416-1426.

- Dikshit R, Gupta PC, Ramasundarahettige C, Gajalakshmi V, Aleksandrowicz L, et al. Cancer mortality in India: a nationally representative survey. *The lancet*. 2012; **379 (9828)**: 1790.
- Drury RAB, Wallington EA. Carleton's Histological Technique. 5th ed. Oxford University Press, Oxford, 1980.
- Duman BB, Sahin B, Acikalin A, Ergin M, Zorludemirs. PTEN, Akt, MAPK, p53 and p95 expression to predict trastuzumab resistance in HER2 positive breast cancer. *J BUON*. 2013; **18(1)**:44-50.
- Ejzen A, Lubinski J, Klijn J, et al. Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study. *J Clin Oncol*. 2005; **23**:7491-7496.
- El-Deiry ws, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, et al. WAF1, a potential mediator of p53 tumor suppression. *Cell*. **1993**; **75(4)**:817-25.
- Elias JM, Gaborc D. A comparison of the peroxidase-anti-peroxidase (PAP), avidin-biotin complex (ABC) and labeled avidin-biotin (LAB) methods for detection of glucagon in paraffin embedded human pancreas. *Am J Clin Pathol*. 1989; **92**:62.
- Elias JM, Gown AM, Nakamura RM, et al. Quality control in immunohistochemistry. Report of a workshop sponsored by the Biological Stain Commission. *Am J Clin Pathol*. 1989; **92**:836-43.
- Elias JM. Immunohistopathology: a practical approach to diagnosis. Chicago: ASCP Press, 1990.
- Esteller M. CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future. *Oncogene*. 2002; **21(35)**:5427-40.

Farooq A, Naveed AK, Azeem Z, and Ahmad T. Breast and ovarian cancer risk due to prevalence of *BRCA1* and *BRCA2* variants in Pakistani population: A Pakistani database report. *Journal of Oncology*. 2011; **2011**:1-8.

Faulk WP, Taylor GM. An immunocolloid method for the electron microscope. *Immunochemistry*. 1971; **8**:1081-3.

Fisher DE. Tumor suppressor genes in human cancer | ISBN 0-98603-807-6.

Foray N, Marot D, Randrianarison V, Venezia ND, Picard D, Perricaudet M, Favaudon V, Jeggo P. Constitutive association of *BRCA1* and c-Abl and its ATM-dependent disruption after irradiation. *Mol Cell Biol*. 2002; **22**:4020-32.

Foulkes WD. Inherited susceptibility to common cancers. *N Engl J Med*. 2008; **359**:2143-2153.

Friedenson B. *BRCA1* and *BRCA2* pathways and the risk of cancers other than breast or ovarian. *MedGenMed*. 2005; **7(2)**:60.

Futreal PA, Liu Q, Shattuck-Eidens D, Cochran C, Harshman K, Tavtigian S, Bennett LM, Haugen-Strano A, Swensen J, Miki Y *et al.* *BRCA1* mutations in primary breast and ovarian carcinomas. *Science*. 1994; **266**:120-2.

García-Closas M, Kelsey K, Hankinson S, Spiegelman D, Springer K, Willett W, Speizer F, Hunter D. Glutathione S-transferase class mu and theta polymorphisms and breast cancer susceptibility. *J. Natl. Cancer Inst*. 1999; **91**:1960-1964.

Gatei M, Scott SP, Filippovitch I, Soronika N, Lavin MF, Weber B, Khanna KK. Role for ATM in DNA damage-induced phosphorylation of *BRCA1*. *Cancer Res*. 2000; **60**:3299-304.

- Gatei M, Zhou BB, Hobson K, Scott S, Young D, Khanna KK. Ataxia telangiectasia mutated (ATM) kinase and ATM and Rad3 related kinase mediate phosphorylation of Brcal at distinct and overlapping sites. *In vivo* assessment using phospho-specific antibodies. *J Biol Chem.* 2001; **276**:17276-80.
- Gatenby R.A., Gillies R.J. Why do cancers have high aerobic glycolysis? *Nat. Rev. Cancer.* 2004; **4**:891–899.
- Ghosh SK, Choudhury B, Hansa J, Mondal R, Singh M, et al. HPV testing for suspected cervical cancer patients from Southern Assam by Fast-PCR. *Asian Pacific Journal of Cancer Prevention.* 2011; **12**:749-751.
- Ginsburg GS. Genomic medicine: 'grand challenges' in the translation of genomics to human health. *Eur J Hum Genet.* 2008; **16**:873–874.
- Giorno R. A comparison of two immunoperoxidase staining methods based on the avidin-biotin interaction. *Diagn Immunol.* 1984; **2**:161-6.
- Garcia-Closas M, Hall P, Nevanlinna H, et al. Heterogeneity of breast cancer associations with five susceptibility loci by clinical and pathological characteristics. *PLoS Genet.* 2008; **4**:e1000054.
- Greenblatt MS, Chappuis PO, Bond JP, Hamel N, Foulkes WD. TP53 mutations in breast cancer associated with BRCA1 or BRCA2 germ-line mutations: distinctive spectrum and structural distribution. *Cancer Res.* 2001; **61**:4092-7.
- Gurr E. Staining animal tissues: practical and theoretical. *London: Leonard Hill,* 1962.
- Haber JE. The many interfaces of Mre11. *Cell.* 1998; **95**:583-6.

- Haines DM, West KH. Immunohistochemistry: forging the links between immunology and pathology. *Vet Immunol Immunopathol.* 2005; **108**:151-6.
- Hall JM, Lee MK, Newman B, Morrow JE, Anderson LA, Huey B, King MC. Linkage of early-onset familial breast cancer to chromosome 17q21. *Science.* 1990; **250**:1684-9.
- Hanahan D and Weinberg RA. Hallmarks of cancer: the next generation. *Cell.* 2011; **144(5)**:646-74.
- Harkin DP, Bean JM, Miklos D, Song YH, Truong VB, Englert C, Christians FC, Ellisen LW, Maheswaran S, Oliner JD, Haber DA. Induction of GADD45 and JNK/SAPK-dependent apoptosis following inducible expression of BRCA1. *Cell.* 1999; **97**:575-86.
- Harris CC, Hollstein M. Clinical implications of the p53 tumor-suppressor gene. *N Engl J Med.* 1993; **329(18)**:1318-27.
- Hedau S, Jain N, Syed A, Husain and Das BC. Novel germline mutations in breast cancer susceptibility genes *BRCA1*, *BRCA2* and *p53* gene in breast cancer patients from India. *Breast Cancer Research and Treatment,* 2004; **88**:177-186.
- Helzlsouer K, Selmin O, Huang H-Y, Strickland P, Hoffman S, Alberg A, et al. Association between glutathione S-transferase M1, P1 and T1 genetic polymorphisms and development of breast cancer. *J. Natl. Cancer Inst.* 1998; **90**:512-518.
- Hrapchak RB. Selective staining with hematoxylin, applications and theory: a review. *Am J Med Technol.* 1976; **42**:371-379.
- Hsu SM, Raine L. Protein A, avidin, and biotin in immunohistochemistry. *J Histochem Cytochem.* 1981; **29**:1349-53.

- Huang SN, Minassian H, More JD. Application of immunofluorescent staining on paraffin sections improved by trypsin digestion. *Lab Invest.* 1976; **35**:383-90.
- Hughes-Davies L, Huntsman D, Ruas M, Fuks F, Bye J, Chin SF, et al. EMSY links the BRCA2 pathway to sporadic breast and ovarian cancer. *Cell.* 2003; **115**: 523-35.
- Jacobs TW, Prioleau JE, Stillman IE, et al. Loss of tumor marker-immunostaining intensity on stored paraffin slides of breast cancer. *J Natl Cancer Inst.* 1996; **88**:1054-9.
- Käffer S, Bleiweiss IJ. Beyond hematoxylin and eosin—the role of immunohistochemistry in surgical pathology. *Cancer Invest.* 2004; **22**:445-65.
- Jemal A., Bray F., Ferlay J., Ward E., and Forman D. Global cancer statistics. *CA Cancer J Clin.* 2011; **61**: 69-90.
- Jensen HE, Salonen J, Ekfors TO. The use of immunohistochemistry to improve sensitivity and specificity in the diagnosis of systemic mycoses in patients with haematological malignancies. *J Pathol.* 1997; **181**:100-5.
- Jensen ML, Nielsen O, Johansen P, et al. Immunohistochemistry in tumor diagnosis. External quality assessment of 13 Departments of Pathology in Western Denmark. *Appl Immunohistochem.* 1997; **5**:35-44.
- Kang HJ, Yi HJ, Kim HJ, Hong YB, Seong YS, Bae I. BRCA1 negatively IGF-1 expression through an estrogen-responsive element-Like site. *Cell Death Dis.* 2012; **3**(6): e336.
- Kelsey K., Hankinson S, Colditz G, Springer K, Garcia-Closas M, Spiegelman D, et al. Glutathione S-transferase class m deletion polymorphism

- andbreast cancer: results from prevalent versus incident cases. *Cancer Epidemiol. Biomark. Prev.* 1997; **6**:511-515.
- King MC, Marks JH, Mandell JB. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. *Science.* 2003; **302**:643-646.
- Kinzler KW, Vogelstein B. Cancer-susceptibility genes. Gatekeepers and caretakers. *Nature.* 1997; **386(6627)**:761-3.
- Knudson AG Jr. Mutation and cancer: statistical study of retinoblastoma. *Proc Natl Acad Sci USA.* 1971; **68(4)**:820-3.
- Koboldt DC, Fulton RS, Mclellan MD, Schmidt H, et al. Comprehensive molecular portraits of human breast tumours. *Nature.* 2012; **490(7418)**:61-70.
- Kroemer G., Pouyssegur J. Tumor cell metabolism: Cancer's Achilles' heel. *Cancer Cell.* 2008; **13**:472-482.
- Kumar BV, Lakhotia S, Ankathil R, Madhavan J, Jayaprakash PG, et al. Germline *BRCA1* mutation analysis in Indian Breast/Ovarian cancer families. *Cancer Biol Ther*, 2002; **1(1)**:18-21.
- Lalor GC, Martin SL. Studies on haematoxylin and haematein. The colouring principles of logwood. I-Absorption spectra of pure compounds in various solvents and a spectrophotometric method of analysis for haematoxylin and haematein. *J. Soc. Dyers Colourists.* 1959; **5**:513-517.
- Lakhotia and Somasundaram. Conformation Sensitive Gel Electrophoresis for detecting *BRCA1* mutations. *Methods in Molecular Biology.* 2010; **223**:403-414.

- Lancaster JM, Wooster R, Mangion J, Phelan CM, Cochran C, et al. *BRCA2* mutations in primary breast and ovarian cancers. *Nat Genet.* 1996; **13**:238-40.
- Lane DP, Crawford LV. T antigen is bound to a host protein in SV40-transformed cells. *Nature.* 1979; **278(5701)**:261-3.
- Lee E. and Muller W.J. Oncogenes and tumor suppressor genes. *Cold Spring Harb Perspect Biol.* 2010; **2**:a003236.
- Lee H, Trainer AH, Friedman LS, Thistlethwaite FC, Evans MJ, Ponder BA, Venkitaraman AR. Mitotic checkpoint inactivation fosters transformation in cells lacking the breast cancer susceptibility gene, *Brca2*. *Mol Cell.* 1999; **4**:1-10.
- Leong AS, Wright J. The contribution of immunohistochemical staining in tumour diagnosis. *Histopathology.* 1987; **11**:1295-305.
- Levin AJ. p53, the cellular gatekeeper for growth and division. *Cell.* 1997; **88**:323-331.
- Lewis SM. Quality assurance programmes in the United Kingdom. *Ann Ist Super Sanita.* 1995; **31**:53-9.
- Li J, Makrigiorgos GM. COLD-PCR: a new platform for highly improved mutation detection in cancer and genetic testing. *Biochemical Society transactions.* 2009; **37(Pt 2)**:427-432.
- Li J, Wang L, et al. Replacing PCR with COLD-PCR enriches variant DNA sequences and redefines the sensitivity of genetic testing. *Nature medicine.* 2008; **14(5)**:579-584.

Li S, Ting NS, Zheng L, Chen PL, Ziv Y, Shiloh Y, Lee EY, Lee WH. Functional link of BRCA1 and ataxia telangiectasia gene product in DNA damage response. *Nature*. 2000; **406**:210-5.

Liang SX, Pearl M, Liang S, Xiang L, Jia L, et al. Personal history of breast cancer as a significant risk factor for endometrial serous carcinoma in women aged 55 years old or younger. *Int J Cancer*, 2011; **128**(4): 763-70.

Liede A, Malik IA, Aziz Z, Rios P, Kwan E, et al. Contribution of *BRCA1* and *BRCA2* Mutations to Breast and Ovarian Cancer in Pakistan. *Am J Hum Genet*. 2009; **71**(3):595-606.

Lillie RD, Fullmer HM. Histopathologic technique and practical histochemistry. *New York: McGraw-Hill*. 1976.

Lipman NS, Jackson LR, Trudel LJ, et al. Monoclonal versus polyclonal antibodies: distinguishing characteristics, applications, and information resources. *Ilar J*. 2005; **46**:258-68.

Linzer DI, Levine AJ. Characterization of a 54K dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells. *Cell*. 1979; **17**(1):43-52.

Lo PK, Lee JS, Liang X, Han L, Mori T, Fackler MJ, Sadik H, Argani P, et al. Epigenetic inactivation of the potential tumor suppressor gene FOXF1 in breast cancer. *Cancer Res*. 2010; **70**:6047.

Löcke I, Kote-Jarai Z, Bancroft E, Bullock S, Jugurnauth S, et al., Loss of heterozygosity at the BRCA1 and BRCA2 loci detected in ductal lavage fluid from BRCA gene mutation carriers and controls. *Cancer Epidemiol Biomarkers Prev*. 2006; **15**(7):1399-402.

- MacLachlan TK, Somasundaram K, Sgagias M, Shifman Y, et al. BRCA1 effects on the cell cycle and the DNA damage response are linked to altered gene expression. *J Biol Chem.* 2000; **275**:2777-85.
- MacLachlan TK, Takimoto R, El-Deiry WS. BRCA1 directs a selective p53-dependent transcriptional response towards growth arrest and DNA repair targets. *Mol Cell Biol.* 2002; **22**:4280-92.
- Mallory FB. Phospho-molybdic acid haematoxylin. *Anat. Anz.* 1891; **6**:375-376.
- Mancini I, Santucci C, et al. The use of COLD-PCR and high-resolution melting analysis improves the limit of detection of KRAS and BRAF mutations in colorectal cancer. *The Journal of molecular diagnostics.* 2010; **12(5)**:705-711.
- Manne U, Myers RB, Srivastava S, et al. Re: loss of tumor marker immunostaining intensity on stored paraffin slides of breast cancer. *J Natl Cancer Inst.* 1997; **89**:585-6.
- Marmorstein LY, Kinev AV, Chan GK, Bochar DA, Beniya H, et al. A human BRCA2 complex containing a structural DNA binding component influences cell cycle progression. *Cell.* 2001; **104**:247-57.
- Marrack J. Nature of antibodies. *Nature.* 1934; **133**:292-3.
- Mason DY, Sammons R. Alkaline phosphatase and peroxidase for double immunoenzymatic labelling of cellular constituents. *J Clin Pathol.* 1978; **31**:454-60.
- Mathew A, Pandey M, and Rajan B. Do younger woman with non-metastatic & non-inflammatory breast carcinoma have poor prognosis? *World J Surg Oncol*, 2004; **2**:2.

- Metcalfe K, Lubinski J, Lynch HT, Ghadirian P, Foulkes WD, et al. Family history of cancer and cancer risks in women with BRCA1 or BRCA2 mutations. *JNCI*, 2010; **102**:1874-1878.
- Meyer KB, Maia AT, O'Reilly M, et al. Allele-specific up-regulation of FGFR2 increases susceptibility to breast cancer. *PLoS Biol.* 2008; **6**:e108.
- Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, et al. A strong candidate for the breast and ovarian cancer susceptibility gene *BRCA1*. *Science*. 1994; **266**:66-71.
- Mondal R, Ghosh SK. HPV infection, GSTM1-GSTT1 genotypes, mitochondrial mutations and tobacco association with oral cancer from northeast India. *Head Neck Oncology*. 2013; **5(4)**:46.
- Mondal R, Ghosh SK, Talukdar FR, Laskar RS. (2012) Association of mitochondrial D-loop mutations with GSTM1 and GSTT1 polymorphisms in oral carcinoma: A case control study from Northeast India. *Oral Oncol*. 2012. pii: S1368-8375(12)00351-X.
- Monteiro AN, August A, Hanafusa H. Evidence for a transcriptional activation function of BRCA1 C-terminal region. *Proc Natl Acad Sci USA*. 1996; **93**:13595-9.
- Morsingh F, Robinson R. The synthesis of diazilin and haematoxylin. *Tetrahedron*. 1970; **26**:281-289.
- Moynahan ME, Chiu JW, Koller BH, Jasin M. Brcal controls homology-directed DNA repair. *Mol Cell*. 1999; **4**:511-8.
- Moynahan ME, Cui TY, Jasin M. Homology-directed DNA repair, mitomycin-c resistance, and chromosome stability is restored with correction of a Brcal mutation. *Cancer Res*. 2001; **61**:4842-50.

- Nadeau G, Boufaied N, Moisan A, Lemieux KM, Cayanan C, et al. BRCA1 can stimulate gene transcription by a unique mechanism. *EMBO Rep.* 2000; **1(3)**:260-5.
- Nadji M. Immunoperoxidase techniques. I. Facts and artifacts. *Am J Dermatopathol.* 1986; **8**:32-6.
- Nakane PK. Simultaneous localization of multiple tissue antigens using the peroxidase-labeled antibody method: a study on pituitary glands of the rat. *J Histochem Cytochem.* 1968; **16**:557-60.
- Narod SA. Screening of women at high risk for breast cancer. *Preventive medicine,* 2011; **52(3)**:127-130.
- Neuhausen SL, Marshall CJ. Loss of heterozygosity in familial tumors from three BRCA1-linked kindreds. *Cancer Res.* 1994; **54**:6069-72.
- Nowak MA, Micjor F, Iwasa Y. Genetic instability and clonal expansion. *J Theor Biol.* 2006; **241(1)**:26-32.
- Oesterreich S, Fuqua SA. Tumor Suppressor genes in breast cancer. *Endocr Relat,Cancer.* 1999; **6(3)**:405-19.
- Oliveira Am, Ross JS, Fletcher JA. Tumor suppressor genes in breast cancer: the gatekeeper and the caretakers. *Am J Clin Pathol.* 2005; **124**:s16-28.
- Ouchi T, Lee SW, Ouchi M, Aaronson SA, Horvath CM. Collaboration of signal transducer and activator of transcription 1 (STAT1) and BRCA1 indifferent regulation of IFN-gamma target genes. *Proc Natl Acad Sci USA* 2000; **97**:5208-13.
- Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. *CA Cancer J Clin.* 2005; **55**:74-108.

- †Pastore JN, Clampett C, Miller JM, et al. A rapid immunoenzyme immunolabeling technique using EPOS reagens. *J Histotech.* 1995; **18**:35-40.
- Paull TT, Cortez D, Bowers B, Elledge SJ, Gellert M. Direct DNA binding by Brca1. *Proc Natl Acad Sci USA* 2001; **98**:6086-91.
- Paull TT, Rogakou EP, Yamazaki V, Kirchgessner CU, Gellert M, Bonner WM. A critical role for histone H2AX in recruitment of repair factors to nuclear foci after DNA damage. *Curr Biol.* 2000; **10**:886-95.
- †Pharoah PD, Antoniou AC, Easton DF, Ponder BA. Polygenes, risk prediction, and targeted prevention of breast cancer. *N Engl J Med.* 2008; **358**:2796–2803.
- †Prescott RJ, Wells S, Bisset DL, et al. Audit of tumour histopathology reviewed by a regional oncology centre. *J Clin Pathol.* 1995; **48**:245-9.
- Raab SS. The cost-effectiveness of immunohistochemistry. *Arch Pathol Lab Med.* 2000; **124**:1185-91.
- †Rahman N, Stratton MR. The genetics of breast cancer susceptibility. *Annu Rev Genet.* 1998; **32**:95-121.
- †Rastogi RP, Richa, Kumar A, Tyagi MB, Sinha RP. Molecular mechanisms of ultraviolet radiation-induced DNA damage and repair. *Journal of Nucleic Acids.* 2010; **2010**:1-27.
- †Renwick A, Thompson D, Seal S, et al. ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles. *Nat Genet.* 2006; **38**:873-875.

- Rickert RR, Maliniak RM. Intralaboratory quality assurance of immunohistochemical procedures. Recommended practices for daily application. *Arch Pathol Lab Med.* 1989; **113**:673-9.
- Ripperger T, Gadzicki D, Meindl A, Schlegelberger B. Breast cancer susceptibility: current knowledge and implications for genetic counselling. *Eur J Hum Genet.* 2009; **17**:722–731.
- Rivlin N, Brosh R, Oren M, Rotter V. Mutations in the p53 tumor suppressor gene: Important milestones at the various steps of tumorigenesis. *Genes & cancer.* **12**(4): 466-474.
- Rogakou EP, Boon C, Redon C, Bonner WM. Megabase chromatin domains involved in DNA double-strand breaks *in vivo*. *J Cell Biol.* 1999; **146**:905- 16.
- Rosen EM, Fan S, Pestell RG, Goldberg ID. BRCA1 gene in breast cancer. *J Cell Physiol.* 2003; **196**:19-41.
- Roth J. Bullock, G R and Petrusz, P. ed. Techniques in Immunocytochemistry. *Academic Press.* 1982: p. 107-20.
- Roy R, Chun J and Powell SN. *BRCA1 & BRCA2*: different roles in a common pathway of genome protection. *Nature reviews cancer.* 2012; **12**:68-78.
- Ruddon RW. *Cancer Biology.* 2007; New York, Oxford University press.
- Sandhu DS., Sandhu, S., Karwasra RK., and Marwah S. Profile of breast cancer patients at a tertiary care hospital in North India. *Indian Journal of Cancer,* 2010; **17**(1):16-22.
- Saxena S, Rekhi B, Bansal A, Bagga A, Chintamani, et al. Clinico-morphological patterns of breast cancer including family history in a

- New Delhi hospital, India-A cross-sectional study. *World journal of surgical Oncology*, 2005; **3**:67, 1-8.
- Schmitt FC. Utilidade dos métodos imuno-histoquímicos para o diagnostic anatomopatológico. *Rev Hosp Clin Fac Med Sao Paulo*. 1991; **46**:26-30.
- Scully R, Anderson SF, Chao DM, Wei W, Ye L, Young RA, Livingston DM, Parvin JD. BRCA1 is a component of the RNA polymerase II holoenzyme. *Proc Natl Acad Sci USA*. 1997; **94**:5605-10.
- Scully R, Chen J, Plug A, Xiao Y, Weaver D, Feunteun J, Ashley T, Livingston DM. Association of BRCA1 with Rad51 in mitotic and meiotic cells. *Cell*. 1997; **88**:265-75.
- Scully R, Ganesan S, Vlasakova K, Chen J, Socolovsky M, Livingston DM. Genetic analysis of *BRCA1* function in a defined tumor cell line. *Mol Cell*. 1999; **4**:1093-9.
- Scully R and Livingston DM. in search of the tumour-supressor functions of *BRCA1* and *BRCA2*. *Nature*. 2000; **408(6811)**:429-32.
- Shattuck-Eidens D, Oliphant A, McClure M, McBride C, Gupte J, Rubano T, et al. BRCA1 sequence analysis in women at high risk for susceptibility mutations. Risk factor analysis and implications for genetic testing. *JAMA*. 1997; **278(15)**:1242-50.
- Shetty P. India faces growing breast cancer epidemic. *The Lancet*. 2012; **379**:992-3.
- Shi SR, Liu C, Taylor CR. Standardization of Immunohistochemistry for Formalin-fixed, Paraffin-embedded Tissue Sections Based on the Antigen Retrieval Technique: From Experiments to Hypothesis. *J Histochem Cytochem*. 2006; **39**:741-8.

- Shinohara A, Ogawa H, Ogawa T. Rad51 protein involved in repair and recombination in *S. cerevisiae* is a RecA-like protein. *Cell*. 1992; **69**:457-70.
- Silva E, Gatalica Z, Snyder C, Vranic S, Lynch JF, et al. Hereditary breast cancer: part II. Management of hereditary breast cancer: implications of molecular genetics and pathology. *Breast J*. 2008; **14**:14-24.
- Singer SJ. Preparation of an electron-dense antibody conjugate. *Nature*. 1959; **183**:1523-4.
- Smith SA, Easton DF, Evans DG, Ponder BA. Allele losses in the region 17q12-21 in familial breast and ovarian cancer involve the wild-type chromosome. *Nat Genet*. 1992; **2**:128-31.
- Somasundaram K, Zhang H, Zeng YX, Houvras Y, Peng Y, Wu GS, et al. Arrest of the cell cycle by the tumour-suppressor BRCA1 requires the CDK-inhibitor p21WAF1/Cip1. *Nature*. 1997; **389**:187-90.
- Sowter HM and Ashworth A. *BRCA1* and *BRCA2* as ovarian cancer susceptibility genes. *Carcinogenesis*. 2005; **26(10)**:1651-6.
- Stemke-Hale K, Hennessy B, Mills GB and Mitra R. Molecular screening for breast cancer prevention, early detection, and treatment planning: combining biomarkers from DNA, RNA, and protein. *Curr Oncol Rep*. 2006; **8(6)**:484-91.
- Stephens PJ, Tarpey PS, Davies H, Van LP, Greenman C, Wedge DC, Nik-Zainal S, et al. The landscape of cancer genes and mutational processes in breast cancer. *Nature*. 2012; **486(7403)**:400-4.
- Sternberger LA, Hardy Jr PH, Cuculis JJ, et al. The unlabeled antibody enzyme method of immunohistochemistry: preparation and properties of soluble antigen-antibody complex (horseradish peroxidase-

- antihorseradish peroxidase) and its use in identification of spirochetes. *J Histochem Cytochem.* 1970; **18**:315-33.
- Stevens A. The haematoxylin. In: Bancroft JD, Stevens A, et al. Theory and practice of histological techniques. *Edinburgh:Churchill Livingstone,* 1990.
- Stewart ZA, Pietenpol JA. p53 signaling and cell cycle checkpoints. *Chem Res Toxicol.* 2001; **14**(3):243-63.
- Sung P. Catalysis of ATP-dependent homologous DNA pairing and strand exchange by yeast RAD51 protein. *Science.* 1994; **265**:1241-3.
- Swanson PE. Hierarchy: the state of the art in immunohistochemistry. *Am J Clin Pathol.* 1997; **107**:139-40.
- Taylor CR. An exaltation of experts: concerted efforts in the standardization of immunohistochemistry. *Hum Pathol.* 1994; **25**:2-11.
- Thomas JE, Smith M, Tonkinson JL, Rubinfeld B, Polakis P. Induction of phosphorylation on BRCA1 during the cell cycle and after DNA damage. *Cell Growth Differ.* 1997; **8**:801-9.
- Thirthagiri E, Lee SY, Kang P, Lee DS, Toh GT, et al. Evaluation of *BRCA1* and *BRCA2* mutations and risk-prediction models in a typical Asian country (Malaysia) with a relatively low incidence of breast cancer. *Breast Cancer Research.* 2008; **10**:R59.
- Valarmathi MT, Sawhney M, Suryanarayana SV, Deo SS, Shukla NK, et al. Novel germline mutations in the *BRCA1* and *BRCA2* genes in Indian breast and breast-ovarian cancer families. *Hum Mutat.* 2004; **23**:205.
- Velculescu VE, EI-Deiry WS. Biological and clinical importance of the p53 tumor suppressor gene. *Clin Chem.* 1996; **42**(6 Pt 1):858-68.

- Yenkitaraman AR. Functions of *BRCA1* and *BRCA2* in the biological response to DNA damage. *J Cell Sci.* 2001; **114**:3591-8.
- Wang D, Zhang LM, Zhai JX, Liu DW. GSTM1 and GSTT1 Polymorphisms and Colorectal Cancer Risk in Chinese Population: A Meta-Analysis. *Int J Colorectal Dis.* 2012; **27(7)**:901-909.
- Wang Y, Cortez D, Yazdi P, Neff N, Elledge SJ, Qin J. BASC, a super complex of BRCA1-associated proteins involved in the recognition and repair of aberrant DNA structures. *Genes Dev.* 2000; **14**:927-39.
- Wang Z, Sun Y. Targeting p53 for novel anticancer therapy. *Transl Oncol.* 2010; **3(1)**:1-12.
- Warner E, Causer PA. MRI surveillance for hereditary breast-cancer risk. *Lancet.* 2005; **365**:1747-1749.
- Wasielewski R, Komminoth P, Werner M. Influence of fixation, antibody clones, and signal amplification on steroid receptor analysis. *Breast J.* 1998; **44**:33-40.
- Welsh PL, King MC. *BRCA1* and *BRCA2* and the genetics of breast and ovarian cancer. *Human Molecular Genetics.* 2001; **10(7)**:705-713.
- Werner B, Campos AC, Nadji M, et al. Uso prático da imuno-histoquímica em patologia cirúrgica. *J Bras Patol Med Lab.* 2005; **41**:353-64.
- White EA, Kramer RE, Tan MJ, Hayes SD, Harper JW, Howley PM. Comprehensive analysis of host cellular interactions with human papillomavirus E6 proteins identifies new E6 binding partners and reflects viral diversity. *J Virol.* 2012; **86(24)**:13174-86.

- Wick MR. Algorithmic immunohistologic analysis of undifferentiated neoplasms. *United States and Canadian Academy of Pathology Annual Meeting*. 1995.
- Williamson EA, Dadmanesh F, Koeffler HP. BRCA1 transactivates the cyclin-dependent kinase inhibitor p27(Kip1). *Oncogene*. 2002; **21**:3199-206.
- Willis JC. A dictionary of the flowering plants and ferns. *Cambridge: Cambridge University Press*. 1951.
- Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J, Collins N, Gregory S, Gumbs C, Micklem G. Identification of the breast cancer susceptibility gene BRCA2. *Nature*. 1995; **378**:789-92.
- Wooster R, Neuhausen SL, Mangion J, Quirk Y, Ford D, Collins N, Nguyen K, Seal S, Tran T, Averill D *et al*. Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. *Science*. 1994; **265**:2088-90.
- Wu X, Petrini JH, Heine WF, Weaver DT, Livingston DM, Chen J. Independence of R/M/N focus formation and the presence of intact BRCA1. *Science*. 2000; **289**:11.
- Yarden RI, Pardo-Reoyo S, Sgagias M, Cowan KH, Brody LC. BRCA1 regulates the G2/M checkpoint by activating Chk1 kinase upon DNA damage. *Nat Genet*. 2002; **30**:285-9.
- Yaziji H, Barry T. Diagnostic Immunohistochemistry: what can go wrong? *Adv Anat Pathol*. 2006; **13**:238-46.
- Ye Q, Hu YF, Zhong H, Nye AC, Belmont AS, Li R. BRCA1-induced largescale chromatin unfolding and allele-specific effects of cancer-predisposing mutations. *J Cell Biol*. 2001; **155**:911-21.

- Yi SM, Li GY. Null Genotype of *GSTT1* Contributes to Esophageal Cancer Risk in Asian Populations: Evidence from a Meta-Analysis. *Asian Pac J Cancer Prev*. 2012, **13(10)**:4967-4971.
- Yoshida K, Miki Y. Role of BRCA1 and BRCA2 as regulators of DNA repair, transcription, and cell cycle in response to DNA damage. *Cancer Science*. 2004; **95**:866-71.
- Yoshida K, Komatsu K, Wang HG, Kufe D. c-Abl tyrosine kinase regulates the human Rad9 checkpoint protein in response to DNA damage. *Mol Cell Biol*. 2002; **22**:3292-300.
- Yu VP, Koehler M, Steinlein C, Schmid M, Hanakahi LA, van Gool AJ, West SC, Venkitaraman AR. Gross chromosomal rearrangements and genetic exchange between nonhomologous chromosomes following BRCA2 inactivation. *Genes Dev*. 2000; **14**:1400-6.
- Yuan ZM, Shioya H, Ishiko T, Sun X, Gu J, Huang YY, Lu H, Kharbanda S, Weichselbaum R, Kufe D. p73 is regulated by tyrosine kinase c-Abl in the apoptotic response to DNA damage. *Nature*. 1999; **399**:814-7.
- Zhang H, Somasundaram K, Peng Y, Tian H, Bi D, Weber BL, El-Deiry WS. BRCA1 physically associates with p53 and stimulates its transcriptional activity. *Oncogene*. 1998; **16**:1713-21.
- Zhang J and Powell SN. The role of the BRCA1 tumor suppressor in DNA double-strand break repair. *Molecular cancer research*. 2005; **3**:531-9.
- Zhang L, Chen H, Gong M, Gong F. The chromatin remodeling protein BRG1 modulates *BRCA1* response to UV irradiation by regulating ATR/ATM activation. *Front Oncol*. 2013; **3(7)**:1-9.
- Zhang X, Timmermann B, Samadi AK, Cohen MS. Withaferin A induces proteasome-dependent degradation of breast cancer susceptibility gene 1

and heat shock factor 1 proteins in breast cancer cells. *ISRN Biochemistry*. 2012; doi:10.5402/2012/707586.

Zhang ZY, Jin XY, Wu R, Wu LN, Xing R, Yang SJ, Xie Y. Meta-Analysis of the Association between GSTM1 and GSTT1 Gene Polymorphisms and Cervical Cancer. *Asian Pac J Cancer Prev*. 2012; **13(3)**:815-819.

Zhao L, Hsu L, Davidov O, Potter J, Elston R, Prentice R. Population-based family study designs: an interdisciplinary research framework for genetic epidemiology. *Genet. Epidemiol*. 1997; **14**:365-388.

Zheng L, Pan H, Li S, Flesken-Nikitin A, Chen PL, Boyer TG, Lee WH. Sequence-specific transcriptional corepressor function for BRCA1 through a novel zinc finger protein, ZBRK1. *Mol Cell*. 2000; **6**:757-68.

Zhong Q, Chen CF, Li S, Chen Y, Wang CC, Xiao J, Chen PL, Sharp ZD, Lee WH. Association of BRCA1 with the hRad50-hMre11-p95 complex and the DNA damage response. *Science*. 1999; **285**:747-50.